Top entities: Paragon Therapeutics, Rosen Law Firm, United States — Food and Drug Administration, Lawrence Rosen, Philip Kim.

What category does this event fall under?

Regulatory — classified as securities class action.

What is the sentiment of coverage?

Aggregate sentiment score: -30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Sep 01, 2026. Coverage continues to evolve.

Regulatory securities class action

Capricor Securities Fraud Class Action

Q: When did this event occur?

First reported Aug 24, 2026; last updated Sep 01, 2026.

Q: What is the market impact?

General. The class action lawsuit could negatively affect Capricor's stock price and investor confidence, as it raises concerns about the integrity of its regulatory pathway and potential financial liabilities.

Analysis based on 6 articles · First reported Aug 24, 2026 · Last updated Sep 01, 2026

Sentiment

-30

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit could negatively affect Capricor's stock price and investor confidence, as it raises concerns about the integrity of its regulatory pathway and potential financial liabilities. The outcome may also influence the company's ability to secure FDA approval for Deramiocel, impacting its future revenue prospects.

Biotechnology Pharmaceuticals

Event Summary

Rosen Law Firm, a global investor rights law firm, has filed a securities class action lawsuit against Paragon Therapeutics, Inc. (NASDAQ: CAPR) on behalf of purchasers of Capricor securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor and certain defendants made materially false and/or misleading statements or failed to disclose that Capricor adopted changes to the pre-specified statistical analysis plan for clinical data of Deramiocel, a cell therapy, without prior FDA agreement, creating a significant risk that the FDA would not find substantial evidence of effectiveness, thereby jeopardizing regulatory approval for Duchenne muscular dystrophy treatment. When the true details emerged, investors suffered damages. The lead plaintiff deadline is September 28, 2026.

Key Actions

100 Rosen Law Firm filed class action lawsuit Paragon Therapeutics

Entities Involved

priv

Paragon Therapeutics

Capricor is the defendant in the securities class action, facing allegations of misleading investors about its Deramiocel regulatory process. The lawsuit could lead to financial damages and reputational harm, potentially affecting its stock price and regulatory approval prospects.

Importance 100.0 Sentiment -50.0

priv

Rosen Law Firm

Rosen Law Firm is the plaintiff's counsel, representing investors in the class action. The firm stands to gain from a successful settlement or judgment, enhancing its reputation in securities litigation.

Importance 80.0 Sentiment 20.0

govactor

United States — Food and Drug Administration

The FDA is central to the allegations, as the lawsuit claims Capricor made changes to its statistical analysis plan without FDA agreement, raising questions about the regulatory review process for Deramiocel. The FDA's decisions will be critical to the case's outcome.

Importance 60.0 Sentiment 0.0

per

Lawrence Rosen

Lawrence Rosen is a founding partner of Rosen Law Firm and is involved in the case as counsel. His role is to lead the litigation on behalf of investors.

Importance 30.0 Sentiment 10.0

per

Philip Kim

Philip Kim is an attorney at Rosen Law Firm and is listed as a contact for the class action. He is involved in representing the investor class.

Importance 30.0 Sentiment 10.0

Relationships

Paragon Therapeutics related ↔ United States — Food and Drug Administration

Rosen Law Firm related ↔ United States — Food and Drug Administration

Rosen Law Firm related ↔ Lawrence Rosen

Rosen Law Firm related ↔ Philip Kim

United States — Food and Drug Administration related ↔ Lawrence Rosen

United States — Food and Drug Administration related ↔ Philip Kim

Lawrence Rosen managing partner ↔ Philip Kim Lawrence Rosen is the founder and managing partner of Rosen Law Firm, where Philip Kim is a partner, and they actively c

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard